18th Annual Psychopharmacology Update is organized by Global Academy for Medical Education and will be held on Oct 26, 2019 at Kingsgate Conference Center at the University of Cincinnati, Cincinnati, Ohio, United States of America.
Who Should Attend:
The 2019 Psychopharmacology Update is a CME conference designed for child and adolescent psychiatrists, general psychiatrists, geriatric psychiatrists, neuropsychiatrists, pharmacists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders to remission with measurement-based care.
Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 11.5 AMA PRA Category 1 Credit(s)™ (5.5 for the general program and 6 AMA PRA Category 1 Credit(s)™ for completing the pre-conference workshops. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 11.5 (5.5 for the general sessions and 6 for attending the pre-conference workshops) contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined and will be indicated on your certificate.
This well-established one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. At this full-day course, nationally renowned faculty will cover Recent Breakthroughs in Psychopharmacology: Novel Treatments. New for this year are pre-conference workshops on addiction and medical cannabis. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.
At the conclusion of this activity, clinicians should be better able to:
• Explain the neurobiology of addiction and how it can inform treatment.
• Describe special needs and issues related to the pregnant addicted patient, adolescent and elderly addicted populations, and patients with comorbid psychiatric disorders.
• Describe the pharmacology of cannabis and the formulations used for medical purposes.
• Discuss current state of the evidence for the therapeutic use of cannabis.
• Review acute and chronic risks of cannabis use.
• Develop strategies to implement medical cannabis safely and effectively into clinical practice.
• Increase routine screening to identify women with perinatal or postpartum depression.
• Develop treatment strategies for women diagnosed with postpartum depression.
• Discuss the clinical efficacy and safety data regarding glutamatergic agents (such as ketamine and esketamine) as a novel treatment option for patients with treatment-resistant depression (TRD).
• Describe the similarities and differences between the available LAI antipsychotic agents.
• Review the pertinent history of research into psychedelic agents as it pertains to their role in managing psychiatric conditions.
• Describe the mechanism of action of psilocybin and MDMA and their safety data.
• Discuss the state of current research into psychedelic agents and their progress through clinical trials.
• Assess patients with psychiatric disorders for common risk factors for tardive dyskinesia.
• Identify the similarities and differences between FDA-approved VMAT2-inhibitors for tardive dyskinesia.
• Identify strategies to manage clozapine-resistant schizophrenia.
• Describe clinical findings of pimavanserin in the management of clozapine-resistant schizophrenia.
• Review screening and diagnostic assessment approaches for Parkinson’s disease psychosis
• Select an optimal treatment strategy for patients with Parkinson’s disease psychosis.
Topics will include:
• Long-Acting Injectables for Psychotic and Mood Disorders
• Emergence of Hallucinogens as Novel Treatments for Depression, Anxiety and PTSD
• Breakthrough Treatment for Postpartum Depression
• Pharmacotherapy for Tardive Dyskinesia in Mood and Psychotic Disorders
• Treatment for Clozapine-Resistant Psychosis
• Treating Parkinson's Disease Psychosis with a Non-Dopaminergic Agent
• Esketamine for Treatment-Resistant Depression
Friday, October 25, 2019
Optional Pre-conference Workshops (Additional Fee Required)
• Addiction Workshop
• Medical Cannabis for Psychiatrists: Science and Practice Workshop
Time: 10:00 - 18:00
|Contact No. :||+1-973-206-8092
|Registration Type||End Date||Price|
|MDs/ DOs Super Early Fee||12 Aug,2019||USD 175.00|
|MDs/ DOs Early Fee||23 Sep,2019||USD 225.00|
|MDs/ DOs Regular Fee||25 Oct,2019||USD 325.00|
|MDs/ DOs Onsite Fee||26 Oct,2019||USD 395.00|
|NPs / PAs / Other Clinicians Super Early Fee||12 Aug,2019||USD 150.00|
|NPs / PAs / Other Clinicians Early Fee||23 Sep,2019||USD 175.00|
|NPs / PAs / Other Clinicians Regular Fee||25 Oct,2019||USD 275.00|
|NPs / PAs / Other Clinicians Onsite Fee||26 Oct,2019||USD 325.00|
|Resident / Fellow Super Early Fee||12 Aug,2019||USD 65.00|
|Resident / Fellow Early Fee||23 Sep,2019||USD 65.00|
|Resident / Fellow Regular Fee||25 Oct,2019||USD 65.00|
|Resident / Fellow Onsite Fee||26 Oct,2019||USD 75.00|
|Optional Pre-conference Workshop: Addiction Workshop Super Early Fee||12 Aug,2019||USD 99.00|
|Optional Pre-conference Workshop: Addiction Workshop Early Fee||23 Sep,2019||USD 125.00|
|Optional Pre-conference Workshop: Addiction Workshop Regular Fee||24 Oct,2019||USD 145.00|
|Optional Pre-conference Workshop: Addiction Workshop Onsite Fee||25 Oct,2019||USD 175.00|
|Optional Pre-conference Workshop: Medical Cannabis Workshop Super Early Fee||12 Aug,2019||USD 99.00|
|Optional Pre-conference Workshop: Medical Cannabis Workshop Early Fee||23 Sep,2019||USD 125.00|
|Optional Pre-conference Workshop: Medical Cannabis Workshop Regular Fee||24 Oct,2019||USD 145.00|
|Optional Pre-conference Workshop: Medical Cannabis Workshop Onsite Fee||25 Oct,2019||USD 175.00|